HK1081099A1 - Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection - Google Patents

Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection

Info

Publication number
HK1081099A1
HK1081099A1 HK06101073.2A HK06101073A HK1081099A1 HK 1081099 A1 HK1081099 A1 HK 1081099A1 HK 06101073 A HK06101073 A HK 06101073A HK 1081099 A1 HK1081099 A1 HK 1081099A1
Authority
HK
Hong Kong
Prior art keywords
cancer
viral infection
therapeutic treatment
chronic viral
myxoma virus
Prior art date
Application number
HK06101073.2A
Other languages
English (en)
Inventor
Grant Mcfadden
John C Bell
Original Assignee
Robarts Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robarts Res Inst filed Critical Robarts Res Inst
Publication of HK1081099A1 publication Critical patent/HK1081099A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK06101073.2A 2003-03-07 2006-01-24 Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection HK1081099A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45252103P 2003-03-07 2003-03-07
US45539303P 2003-03-18 2003-03-18
PCT/CA2004/000341 WO2004078206A1 (fr) 2003-03-07 2004-03-08 Utilisation du virus du myxome pour le traitement du cancer et des infections virales chroniques

Publications (1)

Publication Number Publication Date
HK1081099A1 true HK1081099A1 (en) 2006-05-12

Family

ID=32965588

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06101073.2A HK1081099A1 (en) 2003-03-07 2006-01-24 Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection

Country Status (12)

Country Link
US (2) US7582614B2 (fr)
EP (1) EP1601376B1 (fr)
JP (2) JP4800924B2 (fr)
KR (1) KR101116858B1 (fr)
AU (1) AU2004216928B2 (fr)
CA (1) CA2517147C (fr)
HK (1) HK1081099A1 (fr)
IL (1) IL170601A (fr)
MX (1) MXPA05009526A (fr)
NZ (1) NZ541951A (fr)
RU (1) RU2362584C2 (fr)
WO (1) WO2004078206A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4800924B2 (ja) * 2003-03-07 2011-10-26 ロバーツ リサーチ インスティテュート 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用
DE102004003572A1 (de) * 2004-01-23 2005-08-18 Bavarian Nordic A/S Monoparamunitätsinducer basierend auf attenuierten Myxomaviren des Kaninchens
KR101479093B1 (ko) * 2005-03-07 2015-01-26 로바츠 리서치 인스티튜트 M135r 결핍 점액종 바이러스 및 이의 치료학적 용도
WO2007143538A2 (fr) * 2006-06-01 2007-12-13 Robarts Research Institute Pike-a renforçant l'infection par les myxomavirus
WO2007143548A2 (fr) * 2006-06-01 2007-12-13 Robarts Research Institute Mutants de virus du myxome destinés au traitement du cancer
PL2717887T3 (pl) 2011-06-09 2018-06-29 University Of Florida Research Foundation, Inc. Sposoby leczenia lub zapobiegania chorobie przeszczep przeciw gospodarzowi
CN109982709A (zh) * 2016-11-17 2019-07-05 Vcn生物科学有限公司 病毒载体在治疗视网膜母细胞瘤中的用途
CN111065732A (zh) 2017-09-11 2020-04-24 Imba-莫利库尔生物技术研究所 肿瘤类器官模型
WO2019177438A1 (fr) * 2018-03-16 2019-09-19 바이로큐어 주식회사 Utilisation combinée d'un réovirus et d'un poxvirus myxomateux pour le traitement du cancer
RU2699754C1 (ru) * 2018-05-08 2019-09-09 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский национальный исследовательский государственный университет имени Н.Г. Чернышевского" Флуоресцирующая клеточная линия глиомы и способ её получения
EP3806888B1 (fr) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Constructions régulatrices dérivées de pde5 et procédés d'utilisation en immunothérapie
KR102093623B1 (ko) * 2018-08-17 2020-03-26 바이로큐어 주식회사 암 치료를 위한 다람쥐폭스 바이러스 및 믹소마폭스 바이러스의 병용
CA3112788A1 (fr) * 2018-09-05 2020-03-12 Arizona Board Of Regents On Behalf Of Arizona State University Plate-forme de virus oncolytique permettant de traiter le cancer hematologique
US11591616B1 (en) 2019-04-22 2023-02-28 Colorado State University Research Foundation Apoptotic upregulation by myxoma virus expressing walleye dermal sarcoma virus orfC

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806347A (en) 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
GB9415320D0 (en) 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
EP0895476B1 (fr) 1996-01-25 2003-06-04 The University Court Of The University Of Glasgow Mutant 1716 de hsv destine au traitement des mesotheliomes
WO1999004026A2 (fr) 1997-07-18 1999-01-28 Chiron Corporation Vecteurs lentiviraux
NZ518945A (en) 1997-10-09 2007-03-30 Wellstat Biologics Corp Treatment of neoplasms with viruses
ES2153284B1 (es) 1998-06-10 2001-09-01 Fundacion Para El Estudio Y De Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos.
EP1390046A4 (fr) 1999-04-15 2005-04-20 Wellstat Biologics Corp Traitement de neoplasmes avec des virus
AU6175000A (en) * 1999-07-12 2001-01-30 Viron Therapeutics, Inc. Novel myxoma genes for immune modulation
JP4800924B2 (ja) * 2003-03-07 2011-10-26 ロバーツ リサーチ インスティテュート 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用
WO2007143545A2 (fr) 2006-06-01 2007-12-13 Robarts Research Institute Signal tnf dans les traitements du virus du myxome

Also Published As

Publication number Publication date
AU2004216928A1 (en) 2004-09-16
AU2004216928C1 (en) 2007-03-08
US20090317362A1 (en) 2009-12-24
NZ541951A (en) 2008-03-28
RU2005131020A (ru) 2006-03-10
CA2517147C (fr) 2011-06-14
AU2004216928B2 (en) 2007-03-08
US7582614B2 (en) 2009-09-01
JP4800924B2 (ja) 2011-10-26
CA2517147A1 (fr) 2004-09-16
JP2006519789A (ja) 2006-08-31
EP1601376B1 (fr) 2012-05-30
RU2362584C2 (ru) 2009-07-27
US20060263333A1 (en) 2006-11-23
IL170601A (en) 2010-11-30
US8227440B2 (en) 2012-07-24
MXPA05009526A (es) 2005-12-15
EP1601376A1 (fr) 2005-12-07
KR20050111349A (ko) 2005-11-24
JP2011157399A (ja) 2011-08-18
WO2004078206A1 (fr) 2004-09-16
KR101116858B1 (ko) 2012-03-06

Similar Documents

Publication Publication Date Title
IL170601A (en) Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection
IL207575A0 (en) Vaccine for prevention and treatment of hiv infection
IL165860A0 (en) Administration of therapeutic viruses
TWI347189B (en) Administration of tlr7 ligands and prodrugs thereof for treatment of infection by hepatitis c virus
EP1594512A4 (fr) Composes destines au traitement d'une infection virale
EP1492563A4 (fr) Compositions et procedes pour le diagnostic et le traitement de l'infection du virus de l'herpes simplex
EP1848418A4 (fr) Utilisation de derives d'acide nordihydroguaiaretique pour traiter des cancers et des infections virales et microbiennes qui resistent aux medicaments
IL185376A0 (en) Use of a combination of myxoma virus and rapamycin for therapeutic treatment
EP1765330A4 (fr) Derives de pyranoindole et utilisation de ceux-ci pour le traitement d'une maladie ou d'une infection provoquee par le virus de l'hepatite c
EP1670507A4 (fr) Vaccin pour le traitement et la prevention de l'infection provoquee par le virus de l'herpes simplex
AU2003225281A8 (en) Materials and methods for prevention and treatment of rna viral diseases
GB0329254D0 (en) Treatment of viral infections
IL178492A0 (en) Cancer treatment using viruses and camptothecins
IL162236A0 (en) Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
FR12C0058I2 (fr) Medicament pour traiter des maladies de peau virales et des maladies tumorales
AU2003287145A1 (en) Interferon drug therapy for the treatment of viral diseases and liver fibrosis
EP1525216A4 (fr) Therapie combinee pour le traitement d'infection vih
AU9279601A (en) Compounds and methods for use thereof in the treatment of cancer or viral infections
GB0329958D0 (en) Treatment of viral infections
NO20041855L (no) Fremgangsmate for behandling av hepatitt C-virusinfeksjon ved behandling av feilpasienter
AU2003299962A1 (en) Interferon drug therapy for the treatment of viral diseases and liver fibrosis
AU2003269133A1 (en) Combination treatment of cancer using a cancer vaccine and a chemotherapeutic drug
EP1482955A4 (fr) Traitement prophylactique et therapeutique de maladies infectieuses et autres maladies utilisant des composes immuno-effecteurs
AU2002327531A1 (en) Therapeutic compositions and methods for treating viral infection
AU2002356673B2 (en) Medicament for the treatment of viral skin and tumor diseases

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20210308